CD44 and SLC1A2 are commonly regulated but do not form a fusion transcript in ER+ breast cancer
Endocrine therapy (ET) is essential for managing ER+ HER2- breast cancer; however, resistance remains a significant clinical challenge. This study investigated whether CD44-SLC1A2 gene fusions, reported in gastrointestinal malignancies, contribute to ET resistance mechanisms in breast cancer. Although no CD44-SLC1A2 fusions were detected, high expression of CD44 and SLC1A2 was associated with poor survival outcomes and identified a therapy-resistant subpopulation sustained by aspartate and glutamate metabolism, highlighting potential metabolic vulnerabilities for future therapeutic intervention.
Authors
- Nicla Lorito (ORCID: https://orcid.org/0000-0003-2354-2622)
- Alfredo Smiriglia (ORCID: https://orcid.org/0000-0001-6654-3962)
- Andrea Morandi (ORCID: https://orcid.org/0000-0002-9222-5332)
- Matteo Benelli (ORCID: https://orcid.org/0000-0003-1227-356X)
- Marina Bacci (ORCID: https://orcid.org/0000-0001-8506-2179)
- Francesca Bonechi (ORCID: https://orcid.org/0009-0009-9420-7339)
- Icro Meattini (ORCID: https://orcid.org/0000-0002-1861-2895)
- Edoardo Pagliantini (ORCID: https://orcid.org/0009-0001-1449-1176)
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Florence (IT)
Publication Details
- Journal
- Molecular and Cellular Biochemistry
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1007/s11010-025-05308-w
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Firenze